Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

Core Viewpoint - Fortress Biotech, Inc. is actively participating in the H.C. Wainwright Annual Royalty Company Virtual Conference, highlighting its commitment to enhancing shareholder value through innovative biopharmaceutical strategies [1]. Company Overview - Fortress Biotech is focused on acquiring and advancing biopharmaceutical assets to enhance long-term shareholder value through product revenue, equity holdings, and dividend and royalty revenue [2]. - The company has eight marketed prescription pharmaceutical products and over 20 programs in development across various therapeutic areas, including oncology, dermatology, and rare diseases [2]. - Fortress has established partnerships with leading academic research institutions and biopharmaceutical companies, such as AstraZeneca and Fred Hutchinson Cancer Center, to maximize the potential of its product opportunities [2]. Conference Participation - Lindsay A. Rosenwald, M.D., the Chairman, President, and CEO of Fortress, will participate in a fireside chat and a panel presentation at the conference, indicating the company's engagement with industry discussions [1][3]. - The conference sessions include a fireside chat scheduled from 2:00 p.m. to 2:30 p.m. ET and a panel presentation from 5:00 p.m. to 6:00 p.m. ET [3].